Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) working group

Neurosurgery

Volumn 70, Issue 1, 2012, Pages 234-243

  Vogelbaum, Michael A ^a   Jost, Sarah ^b   Aghi, Manish K ^c   Heimberger, Amy B ^d   Sampson, John H ^e   Wen, Patrick Y ^f   MacDonald, David R ^g   Van Den Bent, Martin J ^h   Chang, Susan M ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Brain surgery; Clinical trials; End points; Macdonald criteria; Response evaluation

Indexed keywords

CARMUSTINE; GADOLINIUM; PSEUDOMONAS EXOTOXIN;

ARTICLE; BRACHYTHERAPY; CLINICAL ASSESSMENT; FOLLOW UP; GLIOMA; HUMAN; IMAGE ANALYSIS; IMMUNOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOSURGERY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; INTERNATIONAL COOPERATION; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84856114191     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318223f5a7     Document Type: Article

References (78)

1. Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2008.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5): 492-507.
3. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578. (Pubitemid 29368260)
4. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170.
5. Macdonald D, Cascino T, Schold SJ, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280. (Pubitemid 20195640)
6. WHO Handbook for Reporting Results of Cancer Treatment. No. 48. Geneva, Switzerland: World Health Organization Offset Publication; 1979.
7. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214. (Pubitemid 11167383)
8. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol. 2008;5(11):634-644.
9. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol. 2008;29(3):419-424. (Pubitemid 351424049)
10. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Mac-donald's Criteria. J Clin Oncol. 2009;27(18):2905-2908.
11. Cairncross JG, Macdonald DR, Pexman JH, Ives FJ. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology. 1988;38(5):724-726.
12. Watling CJ, Lee DH, Macdonald DR, Cairncross JG. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12(9):1886-1889. (Pubitemid 24349391)
13. Henegar MM, Moran CJ, Silbergeld DL. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg. 1996;84(2):174-179. (Pubitemid 26039466)
14. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217(2):377-384.
15. Ulmer S, Braga TA, Barker FG II, Lev MH, Gonzalez RG, Henson JW. Clinical and radiographic features of peritumoral infarction following resection of glio-blastoma. Neurology. 2006;67(9):1668-1670. (Pubitemid 44747942)
16. Finn MA, Blumenthal DT, Salzman KL, Jensen RL. Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol. 2007;67(3):246-250. (Pubitemid 46274888)
17. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
18. Chawla S, Poptani H, Melhem ER. Anatomic, physiologic and metabolic imaging in neuro-oncology. Cancer Treat Res. 2008;143:3-42.
19. Ullrich RT, Kracht LW, Jacobs AH. Neuroimaging in patients with gliomas. Semin Neurol. 2008;28(4):484-494.
20. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dy¬namic susceptibility-weighted contrast-enhanced perfusion MR imaging meas¬urements. AJNR Am J Neuroradiol. 2009;30(3):552-558.
21. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999;52(4):371-379. (Pubitemid 29505267)
22. Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg. 2006;105(1):34-40. (Pubitemid 43979095)
23. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198. (Pubitemid 32799739)
24. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3):467-473. (Pubitemid 37040405)
25. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156-162.
26. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26(10):2466-2474.
27. Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005;103(6):1227-1233. (Pubitemid 40328094)
28. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549-556. (Pubitemid 26404297)
29. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700-707.
30. Shibamoto Y, Kitakabu Y, Takahashi M, et al. Supratentorial low-grade astro-cytoma: correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer. 1993;72(1):190-195. (Pubitemid 23182071)
31. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8): 1338-1345.
32. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998;64(5):581-587. (Pubitemid 28204142)
33. Cairncross JG, Pexman JH, Rathbone MP, DelMaestro RF. Postoperative contrast enhancement in patients with brain tumor. Ann Neurol. 1985;17(6): 570-572. (Pubitemid 15055574)
34. Sato N, Bronen RA, Sze G, et al. Postoperative changes in the brain: MR imaging findings in patients without neoplasms. Radiology. 1997;204(3):839-846. (Pubitemid 27369051)
35. Cairncross JG, Pexman JH, Rathbone MP. Post-surgical contrast enhancement mimicking residual brain tumour. Can J Neurol Sci. 1985;12(1):75.
36. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538-548.
37. Law M, Oh S, Johnson G, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery. 2006; 58(6):1099-1107. (Pubitemid 43879544)
38. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005;26(4):777-783. (Pubitemid 43079767)
39. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66(6):865-874. (Pubitemid 17085708)
40. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835-841.
41. Smith JS, Cha S, Mayo MC, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg. 2005;103(3):428-438. (Pubitemid 43186633)
42. Matheus MG, Castillo M, Ewend M, et al. CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience. AJNR Am J Neuroradiol. 2004;25(7):1211-1217. (Pubitemid 39095171)
43. Parney IF, Kunwar S, McDermott M, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg. 2005;102(2):267-275. (Pubitemid 43194076)
44. Floeth FW, Aulich A, Langen KJ, Burger KJ, Bock WJ, Weber F. MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma. AJNR Am J Neuroradiol. 2001;22(8):1517-1527. (Pubitemid 32862263)
45. Ross DA, Sandler HM, Balter JM, Hayman JA, Archer PG, Auer DL. Imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors. J Neurooncol. 2002;56(2):175-181. (Pubitemid 34272309)
46. Young GS. Advanced MRI of adult brain tumors. Neurol Clin. 2007;25(4):947-973. (Pubitemid 47600577)
47. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48(9): 1468-1481. (Pubitemid 47397397)
48. Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol. 2009;64(1):12-21.
49. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol. 2007;62(2):109-119. (Pubitemid 46039402)
50. Forsyth PA, Kelly PJ, Cascino TL, et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg. 1995;82(3):436-444.
51. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol. 2006;37(3):272-282. (Pubitemid 43277515)
52. Agbi CB, Bernstein M, Laperriere N, Leung P, Lumley M. Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys. 1992;23(2):321-326.
53. Sneed PK, Gutin PH, Larson DA, et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys. 1994;29(4):719-727. (Pubitemid 24241311)
54. Aiken AH, Chang SM, Larson D, Butowski N, Cha S. Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72(5):1340-1346.
55. Korytko T, Radivoyevitch T, Colussi V, et al. 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys. 2006;64(2):419-424. (Pubitemid 43083428)
56. Xu N, Shu H, Marcus R, Crocker IR. Radiation necrosis after stereotactic radiosurgery for metastatic brain disease. Int J Radiat Oncol Biol Phys. 2007;69(3)(suppl 1):S163-S163.
57. Chin LS, Ma L, DiBiase S. Radiation necrosis following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow up. J Neurosurg. 2001;94(6):899-904. (Pubitemid 32799588)
58. Prager JM, Grenier Y, Cozzens JW, Chiowanich P, Gorey MT, Meyer JR. Serial CT and MR imaging of carmustine wafers. AJNR Am J Neuroradiol. 2000;21(1):119-123. (Pubitemid 30225837)
59. Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008;10(3): 320-329.
60. Vandergrift WA, Patel SJ, Nicholas JS, Varma AK. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg Focus. 2006;20(4):E13.
61. Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res. 2008;14(12):3832-3839.
62. Floeth FW, Wittsack HJ, Engelbrecht V, Weber F. Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma: report of two exceptional cases. Zentralbl Neurochir. 2002;63(1):23-28. (Pubitemid 34594879)
63. Smith MM, Thompson JE, Castillo M, et al. MR of recurrent high-grade as-trocytomas after intralesional immunotherapy. AJNR Am J Neuroradiol. 1996;17(6):1065-1071.
64. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-461. (Pubitemid 351597795)
65. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192-2197.
66. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26(22):3791-3796.
67. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2): 228-247.
68. Aoyama H, Shirato H, Nishioka T, et al. Magnetic resonance imaging system for three-dimensional conformal radiotherapy and its impact on gross tumor volume delineation of central nervous system tumors. Int J Radiat Oncol Biol Phys. 2001;50(3):821-827. (Pubitemid 32519601)
69. Joe BN, Fukui MB, Meltzer CC, et al. Brain tumor volume measurement: com¬parison of manual and semiautomated methods. Radiology. 1999;212(3):811-816. (Pubitemid 29410987)
70. Mazzara GP, Velthuizen RP, Pearlman JL, Greenberg HM, Wagner H. Brain tumor target volume determination for radiation treatment planning through automated MRI segmentation. Int J Radiat Oncol Biol Phys. 2004;59(1):300-312. (Pubitemid 38501535)
71. Moonis G, Liu J, Udupa JK, Hackney DB. Estimation of tumor volume with fuzzy-connectedness segmentation of MR images. AJNR Am J Neuroradiol. 2002;23(3):356-363. (Pubitemid 34241312)
72. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006;8(1):38-46. (Pubitemid 43154449)
73. Shi WM, Wildrick DM, Sawaya R. Volumetric measurement of brain tumors from MR imaging. J Neurooncol. 1998;37(1):87-93. (Pubitemid 28073580)
74. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19(2):551-557. (Pubitemid 32112870)
75. Weltens C, Menten J, Feron M, et al. Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging. Radiother Oncol. 2001;60(1):49-59. (Pubitemid 32532081)
76. Warren KE, Patronas N, Aikin AA, Albert PS, Balis FM. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst. 2001;93(18):1401-1405. (Pubitemid 32936817)
77. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol. 2006;8(2):156-165. (Pubitemid 46542660)
78. Chamberlain MC. Ependymomas.Curr Neurol Neurosci Rep. 2003;3(3):193-199. (Pubitemid 38899002)